Chengdu Huasun Group Inc Ltd (SHE:000790) — Market Cap & Net Worth
Market Cap & Net Worth: Chengdu Huasun Group Inc Ltd (000790)
Chengdu Huasun Group Inc Ltd (SHE:000790) has a market capitalization of $344.09 Million (CN¥2.35 Billion) as of August 1, 2026. Listed on the SHE stock exchange, this China-based company holds position #14015 globally and #4138 in its home market, demonstrating a 1.62% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Chengdu Huasun Group Inc Ltd's stock price CN¥3.77 by its total outstanding shares 623719364 (623.72 Million). See 000790 capex to operating cash flow ratio to understand how much of operating cash flow is reinvested back into capital assets.
Chengdu Huasun Group Inc Ltd Market Cap History: 2015 to 2026
Chengdu Huasun Group Inc Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.02 Billion to $344.09 Million (-5.64% CAGR).
Chengdu Huasun Group Inc Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Chengdu Huasun Group Inc Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.41x
Chengdu Huasun Group Inc Ltd's market cap is 0.41 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.02 Billion | $463.31 Million | -$37.41 Million | 2.21x | N/A |
| 2016 | $817.96 Million | $575.19 Million | $82.50 Million | 1.42x | 9.91x |
| 2017 | $457.12 Million | $590.95 Million | $171.67 Million | 0.77x | 2.66x |
| 2018 | $331.25 Million | $633.42 Million | $31.17 Million | 0.52x | 10.63x |
| 2019 | $408.91 Million | $745.34 Million | $61.63 Million | 0.55x | 6.63x |
| 2020 | $398.00 Million | $759.31 Million | $37.50 Million | 0.52x | 10.61x |
| 2021 | $576.38 Million | $954.94 Million | $55.63 Million | 0.60x | 10.36x |
| 2022 | $413.21 Million | $873.10 Million | $41.22 Million | 0.47x | 10.03x |
| 2023 | $460.44 Million | $1.00 Billion | $27.66 Million | 0.46x | 16.65x |
| 2024 | $355.95 Million | $863.98 Million | -$6.69 Million | 0.41x | N/A |
Competitor Companies of 000790 by Market Capitalization
Companies near Chengdu Huasun Group Inc Ltd in the global market cap rankings as of August 1, 2026.
Key companies related to Chengdu Huasun Group Inc Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #503 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #528 globally with a market cap of $50.48 Billion USD ( CN¥344.98 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #550 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #503 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #528 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.48 Billion | CN¥54.08 |
| #550 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.60 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €15.50 |
Chengdu Huasun Group Inc Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Chengdu Huasun Group Inc Ltd's market cap moved from $1.02 Billion to $ 344.09 Million, with a yearly change of -5.64%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥344.09 Million | -2.58% |
| 2025 | CN¥353.21 Million | -0.77% |
| 2024 | CN¥355.95 Million | -22.69% |
| 2023 | CN¥460.44 Million | +11.43% |
| 2022 | CN¥413.21 Million | -28.31% |
| 2021 | CN¥576.38 Million | +44.82% |
| 2020 | CN¥398.00 Million | -2.67% |
| 2019 | CN¥408.91 Million | +23.45% |
| 2018 | CN¥331.25 Million | -27.54% |
| 2017 | CN¥457.12 Million | -44.12% |
| 2016 | CN¥817.96 Million | -20.18% |
| 2015 | CN¥1.02 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of Chengdu Huasun Group Inc Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $344.09 Million USD |
| MoneyControl | $344.09 Million USD |
| MarketWatch | $344.09 Million USD |
| marketcap.company | $344.09 Million USD |
| Reuters | $344.09 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Chengdu Huasun Group Inc Ltd
Chengdu huasun technology group Inc. , LTD. manufactures and sells medicines, bio-pharmaceutical products, and building steel structures. The company manufactures modern Chinese medicines, Chinese patent medicines, chemical medicines, and drugs. It also engages in the research and development, production, and sale of biological products and biotechnology drugs; and medicines for the treatment of … Read more